Hubei JXBio Pharmaceutical Co.,Ltd.

Hubei JXBio Pharmaceutical Co., Ltd. is located in the Xian’an Economic Development Zone in Hubei Province and specializes in the production of GLP-1 receptor agonist peptides and other peptide APIs. It also undertakes the manufacturing of certain CDMO peptide projects. This production base spans 300 acres, with a total building area of approximately 54,000 square meters. The facility includes four peptide production workshops, a quality control and R&D building, Class A and Class B warehouses, a solvent recovery center, a power center, a solid waste collection area, and a wastewater treatment plant.Hubei JXBio has established 10 GMP-compliant peptide API production lines (including pilot-scale production lines) that meet U.S. FDA, European EMA, and Chinese NMPA cGMP standards. The facility is equipped with dozens of solid-phase and liquid-phase peptide synthesis reactors, with a total reactor volume exceeding 30,000 liters. The company has implemented a comprehensive pharmaceutical quality management system (QMS) and an Environmental, Health, and Safety (EHS) management system. It has successfully passed GMP compliance inspections by the NMPA, multiple third-party quality audits, and EHS audits conducted by globally leading clients.With an annual peptide API production capacity reaching several metric tons, Hubei JXBio is a highly competitive manufacturer of chemically synthesized peptide APIs in both domestic and international markets. The facility leads the industry in single-batch production capacity for GLP-1 peptide products in China, while certain cosmetic peptides have single-batch yields exceeding 100 kg.